Evidence map›Paper›PMID 34789478›Full record

ArticleeNeuro

Precision Mapping of Amyloid-β Binding Reveals Perisynaptic Localization and Spatially Restricted Plasticity Deficits.

Hannah S Actor-Engel, Samantha L Schwartz, Kevin C Crosby, Brooke L Sinnen, Olga Prikhodko, Harrison J Ramsay, Jennifer N Bourne, Christina S Winborn, Alexandra Lucas, Katharine R Smith and 2 more

Open access · goldAbstract read
In one paragraph

Article in eNeuro. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Amyloid-β Causes NMDA Receptor Dysfunction and Dendritic Spine Loss through mGluR1 and AKAP150-Anchored Calcineurin Signaling.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Hannah S Actor-EngelDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Samantha L SchwartzDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Kevin C CrosbyDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Brooke L SinnenDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Olga PrikhodkoDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Harrison J RamsayDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.ORCID 0000-0002-4536-9341
Jennifer N BourneElectron Microscopy Core, University of Colorado Anschutz Medical Campus, Aurora, CO 80045.
Christina S WinbornDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Alexandra LucasDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Katharine R SmithDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Mark L Dell'AcquaDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Matthew J KennedyDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045 matthew.kennedy@cuanschutz.edu.ORCID 0000-0002-7029-7802
University of Colorado Anschutz Medical Campus · US

Funding

University of Colorado Aging Training GrantT32AG000279 · NIA · UNIVERSITY OF COLORADO DENVER · PI Kerrie Moreau · 2001 to 2026
$10.1M
PREDOCTORAL TRAINING PROGRAM IN PHARMACOLOGYT32GM007635 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI DELL'ACQUA, MARK L · 1985 to 2023
$6.1M
Postsynaptic kinase/phosphatase networks in amyloid beta-induced synaptic dysfunctionR01NS110383 · NINDS · UNIVERSITY OF COLORADO DENVER · PI MARK L DELL'ACQUA, Matthew J Kennedy · 2018 to 2026
$5.2M
Novel approaches for interrogating and manipulating synaptic function, structure and plasticityR35NS116879 · NINDS · UNIVERSITY OF COLORADO DENVER · PI Matthew J Kennedy · 2020 to 2026
$4.0M
Neuroscience Training GrantT32NS099042 · NINDS · UNIVERSITY OF COLORADO DENVER · PI Nidia Calero, GIDON S FELSEN · 2016 to 2026
$2.1M
Nanoscale organization of the inhibitory synapse during synaptic plasticityR01MH119154 · NIMH · UNIVERSITY OF COLORADO DENVER · PI SMITH, KATHARINE RACHEL · 2020 to 2024
$2.0M
Mechanisms of beta-amyloid induced synaptic dysfunctionR21AG058005 · NIA · UNIVERSITY OF COLORADO DENVER · PI KENNEDY, MATTHEW J · 2018 to 2019
$423k
An optogenetic tool for acute modulation of inhibitory synaptic functionF32MH123053 · NIMH · UNIVERSITY OF COLORADO DENVER · PI OLAH, SAMANTHA · 2020 to 2023
$216k
Calcineurin activation and scaffolding in A Beta-induced synaptic dysfunctionF32AG071073 · NIA · UNIVERSITY OF COLORADO DENVER · PI PRIKHODKO, OLGA · 2021 to 2023
$210k
NIA NIH HHS F32 AG071073NIA NIH HHS R21 AG058005NIA NIH HHS T32 AG000279NIGMS NIH HHS T32 GM007635NIMH NIH HHS F32 MH123053NIMH NIH HHS R01 MH119154NINDS NIH HHS R01 NS110383NINDS NIH HHS R35 NS116879NINDS NIH HHS T32 NS099042
6 · The paper itself

Abstract

Secreted amyloid-β (Aβ) peptide forms neurotoxic oligomeric assemblies thought to cause synaptic deficits associated with Alzheimer's disease (AD). Soluble Aβ oligomers (Aβo) directly bind to neurons with high affinity and block plasticity mechanisms related to learning and memory, trigger loss of excitatory synapses and eventually cause cell death. While Aβo toxicity has been intensely investigated, it remains unclear precisely where Aβo initially binds to the surface of neurons and whether sites of binding relate to synaptic deficits. Here, we used a combination of live cell, super-resolution and ultrastructural imaging techniques to investigate the kinetics, reversibility and nanoscale location of Aβo binding. Surprisingly, Aβo does not bind directly at the synaptic cleft as previously thought but, instead, forms distinct nanoscale clusters encircling the postsynaptic membrane with a significant fraction also binding presynaptic axon terminals. Synaptic plasticity deficits were observed at Aβo-bound synapses but not closely neighboring Aβo-free synapses. Thus, perisynaptic Aβo binding triggers spatially restricted signaling mechanisms to disrupt synaptic function. These data provide new insight into the earliest steps of Aβo pathology and lay the groundwork for future studies evaluating potential surface receptor(s) and local signaling mechanisms responsible for Aβo binding and synapse dysfunction.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesHumansNeuronal PlasticityNeuronsSynapsesAmyloid beta-Peptidesamyloid-βLTPplasticitypostsynaptic densitysuper-resolutionsynapse

Identifiers

PMID34789478
PMCPMC8687484
OpenAlexW3211533669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.